ArticleGeroScience2026
Plasma lipidomic fingerprinting enables high-accuracy biomarker discovery for Alzheimer's disease: a targeted LC-MRM/MS approach.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identifying the shared genes and their related microRNAs, metabolites, and pathways in ischemic stroke and epilepsy.Scientific reports · 2026Article
- Nutritional substrates and microglial metabolic fitness in brain aging and Alzheimer's disease: from lipid handling to TREM2-linked translation.Frontiers in nutrition · 2026Review
- Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer's Disease: A Targeted Mass Spectrometry and Machine Learning Approach.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dysregulation of lipid metabolism is increasingly recognized as a key factor in the pathogenesis of Alzheimer's disease (AD). Unfortunately, an accurate lipidomic fingerprints in AD patients' biofluids remains challenging. A comprehensive analysis of plasma samples from 26 patients with AD and 30 healthy individuals was performed using untargeted and targeted lipidomics techniques with strict lipid annotation criteria. By monitoring characteristic fragments per precursor, we achieved precise lipid characterization and quantification for approximately 270 lipid species. Multivariate statistical analysis revealed a distinct lipid profile between AD patients and controls, with 72 lipids significantly altered (FC > 1.5 or < 0.667, VIP > 1, P < 0.05). Notably, a biomarker analysis based on the multivariate exploratory receiver operating characteristic (ROC) curve identified a comprehensive panel consisting of 10 novel lipids as potential markers for AD, achieving 98.2% accuracy with a favorable auxiliary diagnostic value (area under curve of 0.995). Additionally, the higher levels of SM(d18:1/16:0), SM(d18:1/18:1), and LPE 18:0 were strongly correlated with the clinical dementia rating (CDR) and mini-mental state examination (MMSE) scores, underscoring the therapeutic potential of lipid modulation in AD. These findings reveal the intricate relationship between lipid alterations and AD pathology and emphasize the necessity for LC-MRM/MS lipidomics with rigorous criteria in the discovery of reliable biomarkers, enriching our understanding of lipid roles in neurodegenerative processes and informing future mechanistic investigations and drug target development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.